Patients undergoing elective stenting might be protected from contrast-induced nephropathy if given alprostadil intravenously up to three days after their procedure, according to a randomized study of 480 patients. This benefit of the vasodilator was consistent across subgroups, including those with diabetes. (Catheterization and Cardiovascular Interventions)